4584 Stock Overview
Develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Kidswell Bio Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥118.00 |
| 52 Week High | JP¥185.00 |
| 52 Week Low | JP¥88.00 |
| Beta | 0 |
| 11 Month Change | 2.61% |
| 3 Month Change | -9.92% |
| 1 Year Change | -23.87% |
| 33 Year Change | -77.35% |
| 5 Year Change | -87.15% |
| Change since IPO | -66.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4584 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 6.3% | -5.5% | -0.4% |
| 1Y | -23.9% | 15.4% | 11.4% |
Return vs Industry: 4584 underperformed the JP Biotechs industry which returned 15.4% over the past year.
Return vs Market: 4584 underperformed the JP Market which returned 11.4% over the past year.
Price Volatility
| 4584 volatility | |
|---|---|
| 4584 Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 7.6% |
| 10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4584's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4584's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Shinya Kurebayashi | www.kidswellbio.com |
Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease.
Kidswell Bio Corporation Fundamentals Summary
| 4584 fundamental statistics | |
|---|---|
| Market cap | JP¥4.80b |
| Earnings (TTM) | -JP¥301.95m |
| Revenue (TTM) | JP¥1.88b |
0.0x
P/S Ratio0.0x
P/E RatioIs 4584 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4584 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.88b |
| Cost of Revenue | JP¥721.70m |
| Gross Profit | JP¥1.16b |
| Other Expenses | JP¥1.46b |
| Earnings | -JP¥301.95m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 4584 perform over the long term?
See historical performance and comparison